Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00391
|
|||||
| Drug Name |
Cerivastatin
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Hyperlipidaemia [ICD11:5C8Z] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C26H34FNO5
|
|||||
| Canonical SMILES |
CC(C)C1=C(C(=C(C(=N1)C(C)C)COC)C2=CC=C(C=C2)F)C=CC(CC(CC(=O)O)O)O
|
|||||
| InChI |
InChI=1S/C26H34FNO5/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32)/b11-10+/t19-,20-/m1/s1
|
|||||
| InChIKey |
SEERZIQQUAZTOL-ANMDKAQQSA-N
|
|||||
| CAS Number |
CAS 145599-86-6
|
|||||
| Pharmaceutical Properties | Molecular Weight | 459.5 | Topological Polar Surface Area | 99.9 | ||
| Heavy Atom Count | 33 | Rotatable Bond Count | 11 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 7 | |||
| XLogP |
3.6
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10167
,10299839
,103541455
,104635877
,10852026
,126681828
,134339434
,134339836
,135259857
,135650063
,137002687
,142742086
,14809054
,14858094
,160963785
,164788182
,164807583
,176484089
,179116613
,184546299
,198953954
,223659548
,223898596
,226406536
,226406537
,241035409
,252347182
,36888654
,46505877
,46518451
,48415746
,50067077
,50070698
,50728881
,51091965
,56312092
,56313141
,56313595
,7978896
,822164
,92308707
,93166525
,93578306
|
|||||
| ChEBI ID |
CHEBI:3558
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [3] | ||
| NTCP | Transporter Info | Sodium/taurocholate cotransporting polypeptide | Substrate | [4] | ||
| OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [5] | ||
| OATP1B3 | Transporter Info | Organic anion transporting polypeptide 1B3 | Substrate | [5] | ||
| OATP2B1 | Transporter Info | Organic anion transporting polypeptide 2B1 | Substrate | [6] | ||
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Cerivastatin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. | |||||
| 3 | Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. | |||||
| 4 | Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica. 2011 Jan;41(1):24-34. | |||||
| 5 | FDA Drug Development and Drug Interactions | |||||
| 6 | pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm. 2011 Aug 1;8(4):1303-13. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.